Cetera Investment Advisers Purchases 5,004 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cetera Investment Advisers raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,362 shares of the medical equipment provider's stock after purchasing an additional 5,004 shares during the quarter. Cetera Investment Advisers' holdings in Lantheus were worth $2,768,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Janus Henderson Group PLC increased its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after purchasing an additional 2,610,118 shares during the period. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after buying an additional 30,891 shares during the period. Finally, Silvercrest Asset Management Group LLC lifted its holdings in Lantheus by 39.1% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock valued at $87,124,000 after buying an additional 273,838 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on LNTH shares. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a report on Thursday. Finally, Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $114.50.

Lantheus Stock Up 5.8%

Shares of NASDAQ:LNTH traded up $2.99 during mid-day trading on Thursday, reaching $54.86. 3,899,545 shares of the stock were exchanged, compared to its average volume of 1,730,372. The company has a quick ratio of 5.46, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The company has a market cap of $3.80 billion, a P/E ratio of 14.59 and a beta of 0.14. The stock's 50 day simple moving average is $76.68 and its 200-day simple moving average is $87.17.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the firm posted $1.69 EPS. Lantheus's revenue was up .8% compared to the same quarter last year. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.